Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04730622
Other study ID # OsteoSarcopenia
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 23, 2020
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source Istituto Ortopedico Rizzoli
Contact Gemma Di Pompo, M.Sc.
Phone +39 0516366748
Email gemma.dipompo@ior.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study aims to assess the adequacy of a set of clinical and laboratory investigations for identifying the osteosarcopenia status in patients undergoing a hip replacement for a fragility fracture of the femoral neck. The control group will consist of patients undergoing a hip replacement for osteoarthritis, as the decrease in muscle function and bone quality is less severe in this condition than in osteoporosis.


Description:

Osteoporotic hip fractures (fragility fractures) are common in older adults, and the risk of adverse outcomes and mortality is higher in patients affected by osteosarcopenia, a geriatric syndrome in which the low bone mineral density and bone microarchitecture deterioration (osteopenia/osteoporosis) are combined with a decline in mass, strength, and functional capacity of skeletal muscle (sarcopenia). The diagnostic workup currently recommended to establish the severity of osteosarcopenia is hard to implement in individuals who arrive at the orthopedic emergency department with a fragility fracture. On the one hand, the evaluation of motility and physical performance is impracticable in bedridden patients; on the other hand, the surgical treatment priority does not allow performing all the instrumental investigations required for a proper diagnosis. In this context, reliable osteosarcopenia biomarkers could help identify most frail patients and plan for them personalized therapeutic interventions to promote postoperative recovery and reduce the risk of adverse outcomes. Based on the new knowledge on the pathophysiology of osteosarcopenia, the investigators designed a small-scale study that aims to preliminarily verify the adequacy of a set of clinical and laboratory parameters that could be easily applied in hospitalized patients undergoing hip replacement for a fragility fracture. In particular, the investigators planned to assess the following: - muscle performance by SARC-F questionnaire (acronym deriving from five domains considered in the questionnaire, i.e., strength, assistance with walking, rising from a chair, climbing stairs, and falls); - dietary habits through a questionnaire on the intake frequency of food categories; - histological features of osteoporosis and sarcopenia in tissue samples taken from the surgical site; - the serum levels of markers associated with muscle-bone cross-talk (Myostatin, Insulin-like growth factor 1); - the serum levels of the following pro-inflammatory cytokines to get a clearer picture of the presence of the inflammatory state: IL-6, IL-8, TNF-α; - the serum levels of markers such as FGF-21, GDF15, soluble ST2, interesting markers of bone metabolism, indicators of bone mineral density, and modulators of osteoblast-osteoclast activity; - the composition of the gut microbiota. The study includes 100 patients who are candidates for hip replacement surgery (endo- and arthroplasty). As the decrease in muscle function and bone quality is more severe in fragility fractures than in osteoarthritis, the investigators expect to find differences in laboratory and clinical parameters.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Patients who came to observation with femoral neck fracture of possible osteoporotic nature (no or minimal trauma) to be treated with endoprosthesis or hip arthroplasty. - Competent patients who have signed consent to participate in the study (see Informed Consent section of this protocol). Exclusion Criteria: - Previous osteoporotic fractures - Previous prosthetic surgery for orthopedic diseases - Pre-existing clinical conditions that led to permanent immobility - Neoplastic diseases - Autoimmune diseases - Severe myopathies - Chronic viral infections (HBV, HCV, HIV); - Chronic treatment with anti-osteoporotic drugs, immunosuppressive drugs, and insulin - Paget's disease

Study Design


Intervention

Diagnostic Test:
SARC-F questionnaire
Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.
Bone tissue histology
Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.
Muscle tissue histology
Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.
Myostatin serum levels
Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.
Insulin-like growth factor 1 (IGF-1) serum levels
Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.
Other:
Frequency food questionnaire
Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.
Gut microbiota profiling
Assessment of gut microbiome composition on stool samples.

Locations

Country Name City State
Italy Istituto Ortopedico Rizzoli Bologna

Sponsors (1)

Lead Sponsor Collaborator
Istituto Ortopedico Rizzoli

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Kirk B, Al Saedi A, Duque G. Osteosarcopenia: A case of geroscience. Aging Med (Milton). 2019 Sep 8;2(3):147-156. doi: 10.1002/agm2.12080. eCollection 2019 Sep. — View Citation

Kirk B, Zanker J, Duque G. Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers. J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):609-618. doi: 10.1002/jcsm.12567. Epub 2020 Mar 22. — View Citation

Wong RMY, Wong H, Zhang N, Chow SKH, Chau WW, Wang J, Chim YN, Leung KS, Cheung WH. The relationship between sarcopenia and fragility fracture-a systematic review. Osteoporos Int. 2019 Mar;30(3):541-553. doi: 10.1007/s00198-018-04828-0. Epub 2019 Jan 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Characterization of gut microbiota The "Next Generation Sequencing" technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to assess alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between individuals). Through study completion, an average of 1 year.
Primary Acceptability of the SARC-F questionnaire The number of patients able to provide answers divided by the total number of enrolled patients. Within 24 hours of admission
Primary Frequency of positive SARC-F questionnaire in cases (fragility fractures) and controls (osteoarthritis) The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit a positive SARC-F questionnaire.
The SARC-F is positive and indicates potential sarcopenia if the score point is = or > 4. For each component of the questionnaire (grip strength, assistance with walking, rising from a chair, climbing stairs, and falls), the score may be 0 (no difficulty; no falls), 1 (some difficulty), and 2 (a lot of difficulties and falls). The total score may range from 0 to 10.
Within 24 hours of admission
Primary Presence of histological features of osteoporotic bone in cases (fragility fractures) and controls (osteoarthritis) The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit histological features of osteoporotic bone.
The presence of osteoporotic bone will be proved based on the following histological features: loss of connected trabecular bone, altered matrix mineralization, the prevalence of adipose tissue compared to bone marrow, presence of osteoclasts.
Through study completion, an average of 1 year.
Primary Presence of histological features of muscle atrophy in cases (fragility fractures) and controls (osteoarthritis) The percentage of cases (fragility fractures) and controls (osteoarthritis) who exhibit histological features of muscle atrophy.
The presence of muscle atrophy will be proved based on the following histological features: decrease in size and number of type II myofibers, presence of necrosis or fibro-adipose replacement, decrease in satellite cell number.
Through study completion, an average of 1 year.
Primary Myostatin serum levels in cases (fragility fractures) and controls (osteoarthritis) The immunoenzymatic quantification of circulating Myostatin (µg/L) will be performed on serum samples obtained from peripheral venous blood. The results will be aggregated as mean ± standard error of the mean, median, and min-max range. Through study completion, an average of 1 year.
Primary Insulin-like growth factor 1 (IGF-1) serum levels in cases (fragility fractures) and controls (osteoarthritis) The immunoenzymatic quantification of circulating IGF-1 (µg/L) will be performed on serum samples obtained from peripheral venous blood. The results will be aggregated as mean ± standard error of the mean, median, and min-max range. Through study completion, an average of 1 year.
Primary Acceptability of the Frequency Food Questionnaire The number of patients able to provide answers divided by the total number of enrolled patients. Within 24 hours of admission
Primary Frequency of intake of the different food categories in cases (fragility fractures) and controls (osteoarthritis) The percentages of cases (fragility fractures) and controls (osteoarthritis) who assume never/rarely or regularly the different food categories. Within 24 hours of admission
Secondary Frequency of positive SARC-F questionnaire in patients with and without osteoporotic bone The percentage of patients with and without osteoporotic bone who exhibit a positive (= or > 4) or negative (< 4) SARC-F questionnaire. Through study completion, an average of 1 year.
Secondary Frequency of positive SARC-F questionnaire in patients with and without muscle atrophy The percentage of patients with and without muscle atrophy who exhibit a positive (= or > 4) or negative (< 4) SARC-F questionnaire. Through study completion, an average of 1 year.
Secondary Myostatin serum levels in patients with positive and negative SARC-F questionnaire Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with positive (= or > 4) and negative (< 4) SARC-F questionnaire. Through study completion, an average of 1 year.
Secondary Myostatin serum levels in patients with and without osteoporotic bone Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without osteoporotic bone. Through study completion, an average of 1 year.
Secondary Myostatin serum levels in patients with and without muscle atrophy Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without muscle atrophy. Through study completion, an average of 1 year.
Secondary Insulin-like growth factor 1 (IGF-1) serum levels in patients with positive and negative SARC-F questionnaire Mean ± standard error of the mean, median, and min-max range of circulating IGF-1 (µg/L) in patients with positive (= or > 4) and negative (< 4) SARC-F questionnaire. Through study completion, an average of 1 year.
Secondary Insulin-like growth factor 1 (IGF-1) serum levels in patients with and without osteoporotic bone Mean ± standard error of the mean, median, and min-max range of circulating IGF-1 (µg/L) in patients with and without osteoporotic bone. Through study completion, an average of 1 year.
Secondary Insulin-like growth factor 1 (IGF-1) serum levels in patients with and without muscle atrophy Mean ± standard error of the mean, median, and min-max range of circulating Myostatin (µg/L) in patients with and without muscle atrophy. Through study completion, an average of 1 year.
Secondary Frequency of intake of the different food categories in patients with positive and negative SARC-F questionnaire The percentage of patients with positive (= or > 4) and negative (< 4) SARC-F questionnaire who assume never/rarely and regularly the different food categories. Within 24 hours of admission
Secondary Frequency of intake of the different food categories in patients with and without osteoporotic bone The percentage of patients with and without osteoporotic bone who assume never/rarely and regularly the different food categories. Through study completion, an average of 1 year.
Secondary Frequency of intake of the different food categories in patients with and without muscle atrophy The percentage of patients with and without muscle atrophy who assume never/rarely and regularly the different food categories. Through study completion, an average of 1 year.
Secondary Inflammatory serum markers Mean ± standard error of the mean, median, and min-max range of circulating IL-6, IL-8, TNF-a in patients Through study completion, an average of 1 year.
Secondary Serum markers of bone metabolism Mean ± standard error of the mean, median, and min-max range of circulating FGF-21, GDF15, ST2 in patients Through study completion, an average of 1 year.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05773261 - Clinical Investigation Comparing Two Different Ultra-porous Coated Surfaces of Uncemented Cups N/A
Recruiting NCT05223777 - KINCISE™ Surgical Automated System in Total Hip Arthroplasty (THA) N/A
Recruiting NCT04731077 - Avenir Complete Post-Market Clinical Follow-Up Study N/A
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Not yet recruiting NCT06162195 - The ACTIVE Trial: A Prospective Randomised Control Trial Of The H1 Implant Versus Total Hip Replacement N/A
Withdrawn NCT02743208 - Evaluation of a Short Femoral Stem in Total Hip Arthroplasty N/A
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Active, not recruiting NCT02229279 - Evaluation of Teleconsulting on Rehabilitation After Hip and Knee Surgical Procedures N/A
Active, not recruiting NCT02851992 - A Prospective Study to Evaluate Long-term Clinical Outcomes of the GTS Cementless Femoral Stem N/A
Completed NCT01700933 - Dose-response: Exercise Therapy on Hip Osteoarthritis N/A
Completed NCT01618708 - A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip N/A
Completed NCT01214954 - Early Rehabilitation After Total Hip Replacement N/A
Active, not recruiting NCT00294424 - Study on Costs and Effects of Waiting Time in Total Hip and Knee Replacements N/A
Terminated NCT00588861 - Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Shell Using Simplex® or Palacos® Bone Cement N/A
Withdrawn NCT05054595 - Audio-Recorded vs. Nurse-Led Brief Mindfulness-Based Intervention N/A
Terminated NCT00973141 - A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain Phase 2
Recruiting NCT05014113 - H-28 DELTA ST-C and Minima Retrospective Study.
Completed NCT01066936 - Mini Stem DEXA (Dual Energy X-ray Absorptiometry)
Recruiting NCT06185036 - Histological Validation of dGEMRIC Indices as a Quantitative Biomarker for Cartilage Damage in the Hip Joint